News >

Pembrolizumab Active in BCG-Unresponsive NMIBC

Wayne Kuznar
Published: Wednesday, Oct 24, 2018

Ronald de Wit, MD, PhD

Ronald de Wit, MD, PhD

An interim analysis of an ongoing single-arm open-label phase II study showed encouraging antitumor activity with pembrolizumab (Keytruda) in patients with high-risk nonmuscle invasive bladder cancer (NMIBC) that is unresponsive to Bacillus Calmette-Guérin (BCG) who refused or were ineligible for cystectomy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication